Answers are grounded in this paper and cite their sources.
Ceftibuten is an established, oral, third-generation cephalosporin in early clinical development in combination with an oral prodrug of avibactam for the treatment of complicated urinary tract infections, including acute pyelonephritis. We evaluated the in vitro activity of ceftibuten-avibactam against 1,165 Enterobacterales isolates selected from the 2016–2020 ATLAS global surveillance program based upon their β-lactamase genotype, β-lactam-susceptible phenotype, species identification, and specimen source (95.8% urine).
No takes yet. Share an insight, caveat, or question.
Karlowsky et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: